Nafamostat mesylate-induced hyperkalemia in critically ill patients v

ALL IMAGES VIDEOS

1,410 Results   Any time ▾

Nafamostat mesylate treatment in combination with ...
https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03078-z ▾

May 22, 2020 · This is the first report on **nafamostat** mesylate treatment in combination with favipiravir against **Covid-19**. In comparison with previous **reports** about **critically ill patients with Covid-19**, our **case** series also demonstrated a high number of **patients** (8 [73%]) who required MV requirement; however, the mortality rate was low (1 **patient** [9%]).

Cited by: 4   **Author:** Kent Doi, Mahoko Ikeda, Naoki Hayase, ...
Publish Year: 2020

Critical Care | COVID-19 UPDATES	Sep 04, 2020
Preventing the clinical manifestations and disease ...	Aug 18, 2020
Adverse events associated with nafamostat mesylate and ...	Aug 12, 2020
Comparison between nafamostat mesilate and unfractionated ...	Mar 15, 2015

See more results

(PDF) Nafamostat mesylate treatment in combination with ...
https://www.researchgate.net/publication/342668650...

Dec 01, 2020 · PDF | On Dec 1, 2020, Kent Doi and others published **Nafamostat** mesylate treatment in combination with favipiravir for **patients critically ill with Covid-19**: a **case** ...

Efficacy of Nafamostat in Covid-19 Patients (RACONA Study ...
https://clinicaltrials.gov/ct2/show/NCT04352400 ▾

Apr 20, 2020 · Efficacy of **Nafamostat** in **Covid-19 Patients** (RACONA Study) (RACONA) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a

Searc

Turn off

1,540 Results   Any time ▾

Nafamostat mesylate treatment in ... - Critical Care
https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03078-z ▾

May 22, 2020 · This is the first report on **nafamostat** mesylate treatment in combination with favipiravir against **Covid-19**. In comparison with previous **reports** about **critically ill patients with Covid-19**, our **case** series also demonstrated a high number of **patients** (8 [73%]) who required MV requirement; however, the mortality rate was low (1 **patient** [9%]).

Cited by: 6   **Author:** Kent Doi, Mahoko Ikeda, Naoki Hayase, Kyo...
Publish Year: 2020

Critical Care | COVID-19 UPDATES	Sep 01, 2020
Preventing the clinical manifestations and disease ...	Aug 18, 2020
Adverse events associated with nafamostat ...	Aug 12, 2020
Comparison between nafamostat mesilate and unfractionated ...	Mar 15, 2015

See more results

Efficacy of Nafamostat in Covid-19 Patients (RACONA Study ...
https://clinicaltrials.gov/ct2/show/NCT04352400 ▾

Apr 20, 2020 · Efficacy of **Nafamostat** in **Covid-19 Patients** (RACONA Study) (RACONA) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.

(PDF) Nafamostat mesylate treatment in combination with ...
https://www.researchgate.net/publication/342668650...

In light of this, we recently reported a **case**-series study where 11 **critically ill patients with COVID-19**

Nafamostat mesylate-induced hyperkalemia in critically ill patients with COVID-19: Four case reports

Nafamostat and hyperkalemia in COVID-19 patients

Abstract

BACKGROUND

Nafamostat mesylate (NM) may prove to be one of the key drugs effective against COVID-19 because of its anti-viral properties and the potential to manage coagulopathy. However, NM tends to increase serum potassium levels.

CASE SUMMARY

We observed hyperkalemia immediately after NM administration (200mg/day) in four

Nafamostat mesylate-induced hyperkalemia in critically ill patients

ALL   IMAGES   VIDEOS

1,540 Results   Any time ▾

Nafamostat mesylate treatment in ... - Critical Care

https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03078-z ▾

May 22, 2020 · This is the first report on **nafamostat** mesylate treatment in combination with favipiravir against **Covid-19**. In comparison with previous **reports** about **critically ill patients with Covid-19**, our **case** series also demonstrated a high number of **patients** (8 [73%]) who required MV requirement; however, the mortality rate was low (1 **patient** [9%]).

Cited by: 6   **Author:** Kent Doi, Mahoko Ikeda, Naoki Hayase, ...
Publish Year: 2020

Critical Care | COVID-19 UPDATES	Sep 01, 2020
Preventing the clinical manifestations and disease ...	Aug 18, 2020
Adverse events associated with nafamostat ...	Aug 12, 2020
Comparison between nafamostat mesilate and unfractionated ...	Mar 15, 2015

See more results

Efficacy of Nafamostat in Covid-19 Patients (RACONA Study ...

https://clinicaltrials.gov/ct2/show/NCT04352400 ▾

Apr 20, 2020 · Efficacy of **Nafamostat** in **Covid-19 Patients** (RACONA Study) (RACONA) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.

(PDF) Nafamostat mesylate treatment in combination with ...

https://www.researchgate.net/publication/342668650_Nafamostat_mesylate_treatment_in...

In light of this, we recently reported a **case**-series study where 11 **critically ill patients with COVID-19** were successfully treated with **nafamostat** in combination with favipiravir, [17] ...

What every Intensivist should know about COVID-19